3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myeloid, Acute
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Leukemia
2
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Histiocytosis
1
Hemoglobinuria, Paroxysmal
1
Hemoglobinuria
1
Graft vs Host Disease
1
Congenital Abnormalities
1
Blast Crisis
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Sunitinib
64
Nivolumab
42
pembrolizumab
36
Bevacizumab
32
Everolimus
31
Sorafenib
25
pazopanib
23
Axitinib
23
cabozantinib
14
aldesleukin
13
Ipilimumab
13
temsirolimus
11
Interferon alpha-2
11
Cyclophosphamide
10
avelumab
9
Magnetic Resonance Spectroscopy
9
Interleukin-2
9
lenvatinib
8
atezolizumab
8
Radiosurgery
8
Gemcitabine
8
Immunoglobulin G
7
Erlotinib Hydrochloride
7
Disulfides
6
fludarabine phosphate
5
Radiotherapy
5
Fluorodeoxyglucose F18
5
peginterferon alfa-2b
4
Vorinostat
4
Tyrosine Kinase Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Renal Cell
×
Muromonab-CD3
×
Clear all
No trials found.